Mar 03, 2025
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Dec 13, 2024
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
Nov 14, 2024
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Oct 21, 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Sep 18, 2024
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Aug 21, 2024
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Aug 12, 2024
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Aug 12, 2024
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
Jul 15, 2024
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Jun 17, 2024
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Jun 07, 2024
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
Apr 11, 2024
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Mar 29, 2024
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Mar 07, 2024
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
Feb 12, 2024
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Feb 07, 2024
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
Jan 03, 2024
Kyverna's KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial